Moderate to severe opioids use disorder. Opioid dependence
Conditions
Interventions
Intervention 1: Intervention group: The intervention group will receive an integrated community reinforcement approach, motivational interviewing, and cognitive, behavioral treatment-based guided smar
Sponsors
Swiss Research Institute of Public Health and Addiction (ISGF)
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Written informed consent Minimal age of 18 years Stabilization on methadone or buprenorphine dosage for at least 2 weeks and a maximum of 8 weeks Ownership of a smartphone Good command of Persian Appropriate geographical access to the study site in Tehran Internet access Positive urine test for morphine or tramadol Opioid dependence based on ICD-11
Exclusion criteria
Exclusion criteria: Diagnosis of concurrent dependence on other substances (except nicotine) Current severe or acute psychiatric disorders.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The percentage of negative urine tests for illicit, non-prescribed use of opioids. Timepoint: Baseline and months 1 to 12. Method of measurement: Urine rapid test.;Retention in treatment and study. Timepoint: Months 1, 2, 3, 6, and 12. Method of measurement: Self-report and treatment record. | — |
Secondary
| Measure | Time frame |
|---|---|
| Days of opioid use during last 7 days. Timepoint: Baseline and months 1 to 12. Method of measurement: Self-report Timeline Follow Back Questionnaire.;Days of street-drug use during last 7 days. Timepoint: Baseline and months 1 to 12. Method of measurement: Self-report TLFB Questionnaire.;Severity of opioid dependence. Timepoint: Baseline and months 1, 2, 3, 6 and 12. Method of measurement: Rapid urine test.;The longest period of abstinence from the illicit opioids. Timepoint: Months 1, 2 and 3. Method of measurement: Urine rapid test.;Score of communicable disease risk-taking behaviors. Timepoint: At the baseline and 3-, 6- and 12-month follow-up. Method of measurement: Blood-borne Virus Transmission Risk Assessment Questionnaire BBV-TRAQ.;Score of perceived stress. Timepoint: At the baseline and 3-, 6- and 12-month follow-up. Method of measurement: Perceived Stress Scale.;Score of depression. Timepoint: At the baseline and 3-, 6- and 12-month follow-up. Method of measurement: Patient Health Questionnaire.;Score of anxiety. Timepoint: At the baseline and 3-, 6- and 12-month follow-up. Method of measurement: Generalized Anxiety Disorder Questionnaire.;Score of Trauma. Timepoint: At the baseline and 3-, 6- and 12-month follow-up. Method of measurement: International Trauma Questionnaire for PTSD.;Score of Alcohol Use Disorder. Timepoint: At the baseline and 3-, 6- and 12-month follow-up. Method of measurement: Alcohol Use Disorder Identification Test (AUDIT-C Questionnaire).;Score of Nicotine Dependence. Timepoint: At the baseline and 3-, 6- and 12-month follow-up. Method of measurement: Fagerstrom Test for Nicotine Dependence Questionnaire.;Number of missed OAT appointments. Timepoint: Months 1, 2, 3, 6 and 12. Method of measurement: Physician report.;Score of Client Satisfaction. Timepoint: Months 1, 2, 3, 6 and 12. Method of measurement: Client Satisfaction Questionnaire.;Score of psychological treatment negative effects. Timepoint: Months 1, 2, 3, 6 and 12. Method | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactAlireza Noroozi
Iranian National Center for Addiction Studies (INCAS)
Outcome results
None listed